The Cooper Companies, Inc. (NASDAQ:COO) Stock Has Consensus Price Target of $71.47 According to Analysts

The Cooper Companies, Inc. (NASDAQ:COO) has earned a consensus recommendation of “Hold” from the nineteen brokerages that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $71.47.

A number of research firms have recently issued reports on COO. Citigroup reissued a “neutral” rating and issued a $60.00 price target (down from $80.00) on shares of Cooper Companies in a research report on Thursday, September 10th. Weiss Ratings raised shares of Cooper Companies from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, September 18th. Wells Fargo & Company set a $61.00 price objective on shares of Cooper Companies and gave the company an “equal weight” rating in a research note on Thursday, September 10th. Mizuho set a $75.00 target price on shares of Cooper Companies and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Finally, Stifel Nicolaus set a $70.00 target price on shares of Cooper Companies and gave the stock a “buy” rating in a research report on Thursday, September 10th.

Cooper Companies Stock Down 0.2%

NASDAQ:COO opened at $56.53 on Friday. The business’s fifty day moving average price is $67.48 and its 200 day moving average price is $67.36. The firm has a market capitalization of $10.75 billion, a price-to-earnings ratio of 19.29, a PEG ratio of 2.30 and a beta of 0.82. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23. Cooper Companies has a 1-year low of $51.01 and a 1-year high of $89.83.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same period last year, the company posted $0.49 EPS. The business’s quarterly revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, sell-side analysts forecast that Cooper Companies will post 4.53 earnings per share for the current fiscal year.

Cooper Companies declared that its board has authorized a share buyback program on Wednesday, September 9th that authorizes the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization authorizes the medical device company to purchase up to 22.7% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s management believes its stock is undervalued.

Insider Transactions at Cooper Companies

In other news, Director Lawrence Kurzius acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was acquired at an average cost of $53.91 per share, for a total transaction of $539,100.00. Following the completion of the acquisition, the director owned 21,099 shares in the company, valued at approximately $1,137,447.09. The trade was a 90.10% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Walter Rosebrough, Jr. acquired 7,000 shares of Cooper Companies stock in a transaction that occurred on Friday, September 11th. The shares were purchased at an average cost of $54.11 per share, with a total value of $378,770.00. Following the transaction, the director owned 17,000 shares of the company’s stock, valued at approximately $919,870. The trade was a 70.00% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have purchased 34,701 shares of company stock valued at $1,880,039. 2.08% of the stock is owned by insiders.

Institutional Investors Weigh In On Cooper Companies

A number of hedge funds and other institutional investors have recently made changes to their positions in COO. Envestnet Portfolio Solutions Inc. grew its stake in shares of Cooper Companies by 112.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 15,784 shares of the medical device company’s stock valued at $1,132,000 after buying an additional 8,366 shares in the last quarter. HBK Investments L P bought a new position in Cooper Companies during the second quarter valued at approximately $31,666,000. Sequoia Financial Advisors LLC raised its position in Cooper Companies by 290.4% during the second quarter. Sequoia Financial Advisors LLC now owns 34,286 shares of the medical device company’s stock valued at $2,459,000 after acquiring an additional 25,504 shares in the last quarter. Tidal Investments LLC lifted its stake in Cooper Companies by 281.4% in the second quarter. Tidal Investments LLC now owns 82,903 shares of the medical device company’s stock valued at $5,945,000 after acquiring an additional 61,165 shares during the last quarter. Finally, National Pension Service lifted its stake in Cooper Companies by 9,314.0% in the second quarter. National Pension Service now owns 526,149 shares of the medical device company’s stock valued at $37,730,000 after acquiring an additional 520,560 shares during the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

About Cooper Companies

CooperCompanies (NASDAQ: COO) is a global medical device company focused on improving vision and advancing women’s health. Its operations are organized primarily through CooperVision and CooperSurgical, which develop, manufacture and distribute products for eye care, fertility and other areas of reproductive health.

CooperVision offers a broad range of contact lenses, including lenses for nearsightedness, farsightedness, astigmatism and presbyopia. Its portfolio includes daily disposable, reusable and specialty lenses, as well as products designed to address the progression of myopia in children and adolescents.